ID: MRFR/Pharma/2730-HCR | 80 Pages | Published By Kinjoll Dey on March 2023
Market Synopsis of Tonsil Cancer Market
The Tonsil cancer Market is projected to reach USD 4,192.3 Million by 2030 at 7.1% CAGR during the forecast period 2022-2030.
Tonsil Cancer is a type of head and neck cancer which develops in the parts of throat and just behind the mouth. Tonsil cancer is also known as the cancer of oropharynx. One of the common symptoms of tonsil cancer is sore throat while some other symptoms are fatigue, hoarseness or a change of voice while speaking, ear pain, bleeding from your mouth, and weight loss. People who drink and smoke have almost double chances of tonsil cancer. Many times tonsil cancer is connected with a virus associated with sexual contact known as human papillomavirus (HPV).
Increasing incidence of tonsil is major driver for the market while other factors such as increasing awareness about this disorder, the introduction of the new treatment or therapies and rising demand from emerging markets of Asia as well as Latin America drives the growth of the global market. New research to cure tonsil cancer is another key driver for the market. The Tonsil Cancer Market is growing moderately and is expected to continue its growth over the forecast period.
FIGURE 1 TONSIL CANCER MARKET SHARE BY TYPE 2016 (%)
Sources: National Cancer Institute, Centers for Disease Control and Prevention, National Center for Biotechnology Information, Directorate of Industries, annual report, white paper, company presentation
Key Players in the Tonsil Cancer Market
Some of the key players in Tonsil Cancer Market: F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (US), Novartis AG(Switzerland), Abbott (US), Beckman Coulter Inc. (US), Debiopharm Group (Switzerland), AbbVie Inc. (US), Bayer AG (Germany, and others.
The tonsil cancer market is segmented on the basis of type, which comprises squamous cell carcinoma, salivary gland cancer, lymphoma, mucosal melanoma, sarcomas, malignant fibrous histiocytoma, Peripheral Neuroectodermal Tumor (PNET), and others. Sarcomas is further sub-segmented into chondrosarcoma, liposarcoma, synovial sarcoma, and others.
On the basis of diagnosis, the market is segmented into physical exam, imaging tests, removing a sample of tissue for testing, and others. Imaging tests is further sub-segmented into Computerized Tomography (CT), Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET), and others.
On the basis of treatments, the market is segmented into surgery, radiation therapy, chemotherapy, rehabilitation, and others. Surgery is further sub-segmented into transoral surgery, transoral robotic surgery, open surgery, reconstructive surgery, and others. Radiation therapy includes external beam radiation therapy, internal radiation therapy, and others. Chemotherapy is further sub-segmented into alkylating agents, plant alkaloids, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, miscellaneous antineoplastics, and others.
On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.
Sources: National Cancer Institute, Centers for Disease Control and Prevention, National Center for Biotechnology Information,, Directorate of Industries, annual report, white paper, company presentation
Regional Analysis of the Tonsil Cancer Market
The Americas dominate the global market for the tonsil cancer. North American countries like US dominates the market while Latin America region is also growing significantly in this region. The US is one of the top revenue generating countries in the global tonsil cancer treatment. Increasing number of patients with tonsil cancer is major driver for this market. North America is holding major market share due to some major factors like easily available treatment facilities, extended insurance cover, and adoption of advanced therapies to cure tonsil cancer.
Europe is the second largest market for tonsil cancer. This region is mainly divided into Eastern Europe and Western Europe. Germany is the largest while UK is the fastest growing market in Europe for tonsil cancer. As per the data published by Cancer Research UK, the incidence rate of head and neck cancer per 1,00,000 population in UK is 11,449 and cases are more in male than female. Availability of advanced healthcare facilities and high expenditure on healthcare are driving the growth for the market.
Asia Pacific region is one of the high potential market for healthcare sector. This region is showing exceptional growth in almost every product and services mainly related to medical field. Increasing cases of tonsil cancer, growing awareness among the patients and rapidly improving healthcare infrastructure are driving the market growth. Relatively low cost healthcare facilities are attracting patients from various high-income nations to get affordable treatments which boosting medical tourism in this region. Government is providing various subsidies and other facilities to improve public health as well as increasing use of insurance facilities are major driving forces for this market.
Lack of awareness of the disorder and limited availability of required healthcare facilities are major restraints for the Middle East & Africa tonsil cancer market due to which this market is expected to have limited growth during the forecast period.Intended Audience
The tonsil cancer market is projected to grow at a 7.1% CAGR between 2022-2030.
The Americas is expected to dominate the tonsil cancer market.
Rising incidence of tonsil and development of new therapies are the key factors driving the growth of the tonsil cancer market.
The tonsil cancer market is predicted to touch USD 4,192.3 Million by 2030.
Major end users of the tonsil cancer market include academic institutes, medical research centers, hospitals and clinics, and others.